Skip to main content
TAK
NYSE Life Sciences

Takeda Issues $539M in Shares for Employee Long-Term Incentive Plan

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Pharmaceutical Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$15.55
Mkt Cap
$49.979B
52W Low
$12.99
52W High
$18.895
52W Position info
20% above low
Off High info
18% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

TAK sits 20% above its 52-week low of $12.99.

Summary

Takeda announced the issuance of approximately $539 million in shares for its employee Long-Term Incentive Plan, a routine but substantial compensation event.


Key Events · Financing and Capital Events · TAK

  • Share Issuance for LTIP

    Takeda will issue 16,989,076 ordinary shares (a mix of new and treasury shares) for its Long-Term Incentive Plan (LTIP) for employees outside of Japan.

  • Significant Value

    The shares are valued at 5,050 yen per share, totaling approximately 85.8 billion yen (about $539 million USD).

  • Employee Compensation

    The issuance is for 10,557 employees, covering Restricted Stock Unit (RSU) and Performance Stock Unit (PSU) awards vesting in 2026.

  • Dilutive Impact

    This issuance represents approximately 0.53% dilution of outstanding shares and 1.08% of the company's market capitalization.


Analysis · TAK · Life Sciences

Takeda is issuing 16.99 million new and treasury shares, valued at approximately $539 million, as part of its Long-Term Incentive Plan (LTIP) for employees outside of Japan. This issuance, representing about 1.08% of the company's market capitalization, is a significant component of employee compensation designed to align interests with shareholders and retain talent. While dilutive, it is a routine execution of an ongoing incentive program.

How filings like this one have moved

In the 30 days to Sep 13, 2026, 29.5% of the 1672 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.22%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, TAK was trading at $15.55 on NYSE in the Life Sciences sector, with a market capitalization of approximately $50B. The 52-week trading range was $12.99 to $18.90. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

TAK - Latest Insights

TAK
Aug 28, 2026, 9:10 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $18.08
Real-time Price: $18.26 info
Change: +$0.180 (+1.00%) info
Market Cap: $58.557B info
TAK
Aug 05, 2026, 9:37 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $16.88
Real-time Price: $18.26 info
Change: +$1.38 (+8%) info
Market Cap: $58.557B info
TAK
Jul 30, 2026, 6:01 AM EDT
Filing Type: 6-K
Importance Score:
7
Price at Filing: $17.70
Real-time Price: $18.26 info
Change: +$0.560 (+3%) info
Market Cap: $58.557B info
TAK
Jul 30, 2026, 2:37 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $17.40
Real-time Price: $18.26 info
Change: +$0.860 (+5%) info
Market Cap: $58.557B info
TAK
Jul 13, 2026, 6:07 AM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $16.37
Real-time Price: $18.26 info
Change: +$1.89 (+12%) info
Market Cap: $58.557B info